This trial is testing a new treatment for melanoma that involves a combination of two drugs. The study is open to people with operable melanoma who have not yet received treatment.
1 Primary · 5 Secondary · Reporting Duration: 12 weeks after start of therapy
Experimental Treatment
33 Total Participants · 1 Treatment Group
Primary Treatment: Nivolumab · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: